Quit Smoking Drugs Market Report 2025

The quit smoking drugs market size has grown rapidly in recent years. It will grow from $39.26 billion in 2024 to $44.62 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to health awareness campaigns, medical advancements, government initiatives, behavioral therapies integration, consumer attitude shifts.

The quit smoking drugs market size is expected to see rapid growth in the next few years. It will grow to $79.99 billion in 2029 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to research and development investments, growing demand for cessation aids, targeted marketing and awareness campaigns, advancements in pharmacotherapy. Major trends in the forecast period include personalized treatment approaches, increasing health consciousness, digital therapeutics and apps, behavioral therapy integration, targeted marketing and education.

The increasing prevalence of smoking addiction is projected to drive the growth of the quit-smoking drug market in the future. Smoking involves inhaling and exhaling vapors from burning plant materials such as marijuana, hashish, tobacco, and others. Quit-smoking drugs are designed to reduce the urge to smoke by alleviating cravings for tobacco, and they are used as prescription medications to manage nicotine withdrawal symptoms, helping individuals quit smoking effectively. For example, in July 2022, Statistics Canada, a government agency based in Canada, reported a 5.8% increase in cigarette production compared to June 2021. Additionally, the total number of cigarettes sold rose by 1.3% from May 2022, reaching 1.4 billion in June 2022. Therefore, the growing prevalence of smoking addiction is driving the expansion of the quit-smoking drug market.

The growth of the quit-smoking drugs market is expected to be further accelerated by the rise of e-commerce. E-commerce, involving the online buying and selling of goods and services, provides a convenient platform for individuals seeking quit-smoking solutions. Quit-smoking drugs are increasingly accessible through online platforms, offering a discreet and user-friendly option for those aiming to quit smoking. For example, in August 2023, the U.S. Census Bureau estimated a 2.1% increase in U.S. retail e-commerce sales for the second quarter of 2023, reaching $277.6 billion. This surge in e-commerce activities contributes to the expansion of the quit-smoking drugs market.

A key trend in the quit-smoking drugs market is the focus on product innovation by major companies to strengthen their market positions. Notably, Swedish Match AB, a tobacco company based in Sweden, introduced ZYN Tobacco Gold in August 2022. ZYN Tobacco Gold is a nicotine pouch with a sweet tobacco flavor, offering a tobacco-free and smoke-free alternative. This innovative product addresses consumer preferences for reduced-risk alternatives, catering to those who wish to avoid tobacco consumption while still enjoying a nicotine kick in smoke-free environments.

Major companies in the quit smoking drugs market are concentrating on developing new formulations and delivery methods, such as generic tablets, to enhance their market leadership across various regions and gain a competitive advantage. Generic varenicline tablets are non-branded alternatives containing varenicline tartrate, which are bioequivalent to the original branded product and are utilized for smoking cessation therapy. For example, in January 2024, Lupin Limited, a pharmaceutical company based in India, launched new varenicline tablets in the United States, available in strengths of 0.5 mg and 1 mg. These tablets are generic versions of Chantix tablets (0.5 mg and 1 mg) produced by PF Prism C.V. and are designed to aid in smoking cessation treatment. As a partial agonist of the nicotinic acetylcholine receptor, varenicline stimulates the release of dopamine, helping to alleviate withdrawal symptoms and cravings associated with nicotine addiction. This dual mechanism reduces the pleasurable effects of smoking while providing some stimulation to minimize withdrawal symptoms.

In September 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, acquired the nicotine replacement therapy business from Haleon plc for $680 million (£500 million). The purpose of this acquisition is to strengthen Dr. Reddy's position in the global consumer healthcare market, particularly by enhancing its over-the-counter (OTC) offerings and expanding its presence in key international markets outside the United States. Haleon plc is a consumer health company based in the UK that specializes in drugs for nicotine addiction.

Major companies operating in the quit smoking drugs market include 22nd Century Group, Cipla Limited, Dr. Reddy's Laboratories, GSK Plc., Johnson & Johnson, NJOY LLC, Novartis AG, Perrigo Company Plc, Pfizer Inc., Philip Morris International, Glenmark Pharmaceuticals Limited, Zydus Cadila Healthcare Limited, Rusan Pharma Ltd., BioCorRx Inc., CV Sciences Inc., Ennaid Therapeutics LLC, Fertin Pharma A/S, Gilla Inc., Hikma Pharmaceuticals PLC, Innovus Pharmaceuticals Inc., IntelGenx Technologies Corp.

North America was the largest region in the quit smoking drugs market in 2024. The regions covered in the quit smoking drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the quit smoking drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Quit smoking drugs are specialized medications used by individuals aiming to quit smoking. These drugs help reduce cravings and alleviate nicotine withdrawal symptoms. They deliver nicotine in alternative forms, such as chewing gum or patches, for a limited period, thus mitigating withdrawal symptoms and the urge to smoke.

The major products within the category of quit-smoking drugs include drug therapy, electronic cigarettes, nicotine inhalers, nicotine replacement therapies, and nicotine sublingual tablets. Drug therapy involves the use of medications to treat or prevent diseases related to smoking cessation. Medications such as Varenicline (Chantix), Bupropion (Zyban), and others are available through various channels, including drug stores, online pharmacies, and retail pharmacies.

The quit smoking drugs market research report is one of a series of new reports that provides quit smoking drugs market statistics, including quit smoking drugs industry global market size, regional shares, competitors with a quit smoking drugs market share, detailed quit smoking drugs market segments, market trends and opportunities, and any further data you may need to thrive in the quit smoking drugs industry. This quit smoking drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The quit-smoking drugs market consists of sales of AXS-05, cytisincline, nadolol, and liraglutide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.